Exact Sciences
Leading cancer screening and diagnostics company known for Cologuard colorectal cancer screening test and Oncotype DX cancer diagnostic tests, using molecular diagnostics to improve cancer detection and treatment decisions.
Notes
Exact Sciences is a leading cancer screening and diagnostics company headquartered in Madison, Wisconsin. The company is best known for Cologuard, an FDA-approved, non-invasive colorectal cancer screening test that can be done at home, which has become one of the most widely used cancer screening tests in the United States.
Beyond Cologuard, Exact Sciences offers a comprehensive portfolio of cancer diagnostics including Oncotype DX tests for breast, colon, and prostate cancer that help guide treatment decisions. The company has grown significantly through acquisitions, including Genomic Health (2019) and Base Genomics (2020).
Exact Sciences is publicly traded on NASDAQ under the ticker EXAS.
Team
- Kevin Conroy - Chairman & CEO
- Jeffrey Elliott - Chief Financial Officer
- Everett Cunningham - Chief Commercial Officer
Additional Research Findings
- Founded in 1995
- Publicly traded: NASDAQ (EXAS)
- Headquarters: Madison, Wisconsin
- Market cap: Multi-billion dollar company
- Flagship products: Cologuard, Oncotype DX
- Acquired Genomic Health in 2019 for ~$2.8 billion
- Acquired Base Genomics in 2020 (methylation-based early cancer detection)
- Over 6,000 employees
- Focus on cancer screening, diagnostics, and treatment guidance
- Strong partnerships with healthcare providers nationwide
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Spur Capital Partners | Boston, Massachusetts, USA | pe | growth | 1 |
| Valiance Asset Management | New York, New York, USA | hedge-fund | growth | 1 |